Shionogi Inc (Shionogi), a subsidiary of Shionogi & Co Ltd, is a pharmaceutical company that develops and commercializes pharmaceutical products to address unmet medical needs and treat chronic diseases. It is a subsidiary of Shionogi & Co Ltd, a Japan-based pharmaceutical company that manufactures and sells pharmaceutical products, diagnostics, and other related products. The company offers a wide range of products in the therapeutic areas of anti-infectives, cardiovascular, pain, women's health, pediatrics, and others. A few of its major products include Mulpleta which is used for thrombocytopenia with chronic liver disease; Methylin is a mild central nervous system stimulant. Other products include Fetroja (cefiderocol) for injection for the treatment of complicated urinary tract infections (cUTIs), HABP/VABP; Mulpleta (lusutrombopag) tablets treatment of thrombocytopenia associated with chronic liver disease.

Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat.

Shionogi is committed to addressing unmet medical needs through its research and development initiatives. The company focuses on developing treatments for infectious diseases, neurology/CNS disorders, metabolic disorders, and oncology. The company focuses on small molecule drug discovery and continues to advance clinical programs for COVID-19, Fragile X syndrome, acute ischemic stroke, and other conditions. The company is also involved in developing novel antibiotics and medications for HIV and influenza and collaborates with strategic partners to research therapies for multi-drug-resistant tuberculosis and neglected tropical diseases. The R&D activities of Shionogi are managed through in-house discovery efforts and strategic partnerships. The company collaborates with pharmaceutical and biotech companies, government organizations, and research institutes to advance scientific research and address global health challenges.